Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast ...

Overall survival, defined as the time from randomization ... status on their preneoadjuvant therapy biopsy specimen and HER2-negative status on their postneoadjuvant therapy residual disease ...

这是一例绝经前 HR+/HER- 晚期乳腺癌患者，该患者还伴有破溃、广泛骨转移和胸膜转移，经过八周期的化疗后胸部肿块明显缩小，骨转移病灶趋于稳定。考虑到患者较为年轻（41 ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...